HE3286

DRUG5 trials

Sponsors

Harbor Therapeutics

Conditions

Insulin ResistanceRheumatoid ArthritisType 2 Diabetes MellitusUlcerative Colitis

Phase 1

Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects

CompletedNCT00555451

Harbor TherapeuticsInsulin Resistance

Start: 2007-10-31End: 2009-09-30Target: 66Updated: 2010-05-13

Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

CompletedNCT00628433

Harbor TherapeuticsUlcerative Colitis

Start: 2008-02-29End: 2009-05-31Updated: 2011-06-14

Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis

CompletedNCT00712114

Harbor TherapeuticsRheumatoid Arthritis

Start: 2008-07-31End: 2009-07-31Updated: 2011-06-14

A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production

CompletedNCT00991107

Harbor TherapeuticsInsulin Resistance

Start: 2009-09-30End: 2010-08-31Updated: 2011-03-09

Phase 2

Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus

CompletedNCT00694057

Harbor TherapeuticsType 2 Diabetes Mellitus

Start: 2008-06-30End: 2010-01-31Updated: 2011-06-14